Approved for use through 07/31/2006, OMB 0651-0031 U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

OCT 2 9 2007 Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known Application Number 10/582,296 April 20, 2007 Filing Date First Named Inventor Benjamin SREDNI et al 1617 Art Unit Examiner Name Not Yet Assigned

Sheet		1	of	2	Attorney	Docket Number	32040		
	•		U.S.	PATENT	DOCUME	ENTS		30 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	_
Examiner Initials*	Cite No. 1	Document Number	Publica	tion Date M-YYYY		Name of Patentee or oplicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	ļ	Number-Kind Code ^{2 (if known)}						riguies Appear	
1		US-5,610,179	11-Mar-	1997	Sredni et al.				
									_
									_
									_
				-					_
									_
									_
									_
			FOREIG	GN PATE	NT DOCU	MENTS			_
Examiner Initials*	Cite No. 1			Publica	ation Date MM-YYYY	Name of Patentee			
		Country Code ³ · Number ⁴ · Kind (Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)		nvi- i i i	Applicant of Cited Docum			
									†
									+
	 								†

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

Date

Considered

Examiner

Signature

Applicant's unique citation designation number (optional).

See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria,

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Complete if Known
Application Number 10/582,296

Filing Date April 20, 2007

First Named Inventor Benjamin SREDNI et al

Group Art Unit 1617

Examiner Name Not Yet Assigned

					Examiner Name	Not Yet Assigne	ed		
Sheet		2	Of	2	Attorney Docket Number	32040			
		OTHER PRIOR	ART - N	NON PATENT	LITERATURE DOCU	MENTS			
Examiner Initials									
	2	Kalechman et al. "Role of Endogenous Cytokines Secretion in Radioprotection Conferred by the Immunomodulator Ammonium Trichloro(Dioxyethylene-0-0')Tellurate", Blood, 85(6): 1555-1561, 1995.							
	3	Kalechman et al. "Synergistic Anti-tumoral Effect of Paclitaxel (Taxol)+AS101 in A Murine Model of B16 Melanoma: Association With Ras-Dependent Signal-Transduction Pathways", International Journal of Cancer, 86: 281-288, 2000.							
	4	Sredni et al. "A New Immunomodulating Compound (AS-101) With Potential Therapeutic Application", Nature, P.1558-1561, 1987.							
	5	Strassmann et al. "The Immunomodulator AS-101 Inhibits IL-10 Release and Augments TNFAlpha and IL-1Alpha Release by Mouse and Human Mononuclear Phagocytes", Cellular Immunology, 176: 180-185, 1997.							

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.